Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Efficacy and safety of cyclosporin in dogs with atopic dermatitis
Cyclosporin A has been introduced in veterinary medicine years ago. Because of severe potential side effects in men, the drug has already undergone a lot of evaluations in dogs. Here is a very interesting new study focussing on the use of Cyclosporin A in dogs with atopic dermatitis, the favorite indication for this substance!

The efficacy of cyclosporin A (CsA) for the treatment of canine atopic dermatitis was evaluated based on the systematic review of prospective clinical trials published between 2001 and 2005.

Ten studies with adequate design characteristics were included.

These studies enrolled 799 dogs, 672 (84%) treated with CsA, 160 (20%) with placebo, 74 (9%) with oral glucocorticoids and 23 (3%) with antihistamines.

Treatment duration varied from 2 weeks to 6 months. For safety analysis, data were available from 660 dogs.

Lesion scores were improved from baseline in the range of 30–52%, 53–84% and 52–69% after 4, 6 and 16 weeks, respectively.

The percentage of dogs with only mild pruritus rose from 0–13% at inclusion to 32–59% and 46–90% after 4 and 12 weeks, respectively. In most studies, the frequency of CsA administration could be reduced to every other day in 40% to 50% of patients after 4 weeks and to twice weekly in 20–26% of the dogs after 12–16 weeks.

Meta-analysis confirmed highly significant effects of CsA compared to placebo, but none between oral CsA and glucocorticoids.

The initial disease severity, age or body weight of subjects did not influence treatment success. Improvement by more than 50% over baseline of lesion scores was predictive of a better response during treatment maintenance.

Vomiting and soft stools/diarrhoea were the most frequent adverse events seen at least once during the studies. These occurred in 25% and 15% of subjects, respectively.

The frequency of each other type of adverse events was lower than 2.1%.

In summary, the administration of CsA for the treatment of canine AD was found to be as effective as that of glucocorticoids, and adverse effects were minimal.



Source: STEFFAN, JEAN, FAVROT, CLAUDE & MUELLER, RALF (2006): A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. In: Veterinary Dermatology 17 (1), 3-16.





Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Variability of SDMA in apparently healthy dogsmembers
Symmetric dimethylarginine (SDMA) is a screening tool for early kidney dysfunction and monitoring treatment in cases of chronic kidney disease (CKD). There are no current studies describing the suitability of this test for use with published population‐based reference intervals. The objectives of this study were to determine the components of biological variability, the index of individuality (IOI), the critical difference between sequential measurements (CD) and the number of measurements required to assess the homeostatic set point (HSP), for both SDMA and serum creatinine (sCr), in apparently healthy dogs.

  • Bioavailability of suppository acetaminophen in dogsmembers
  • Computed tomographic lymphography for lymph node staging in dogs with malignant tumors members
  • Characterization of ocular melanosis-affected canine melanocytesmembers
  • Nasopharyngeal sialoceles in brachycephalic dogsmembers
  • Enterococcus faecium SF68 on serum cobalamin and folate concentrationsmembers
  • Gastrointestinal eosinophilic sclerosing fibroplasia limited to the mesentery in a catmembers
  • Ion acid-base disturbances and associated mortality in dogsmembers
  • First description of ultrasonic bone curette in canine otic surgerymembers
  • Staining hair samples with a modified Wright-Giemsa stain to diagnose feline dermatophytosismembers
  • Oral extended release hydrocodone as analgesia after TPLOmembers
  • 25OH vitamin D3 serum concentration in dogs with acute polyradiculoneuritismembers
  • Type 1 immune mediated polyarthritis in dogs and temporal relationship to vaccination members


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved